AUTHORS
Xiaojian Han, MD, Alexandra Dreyzin, MD2, Arun Kumar Arunachalam, MBBS, MD3, Jessica Kerr, MSc Immunology4, Malaak Jawhari5, Keri Toner, MD6, Nirali N. Shah, MD, MHSc7, J. Joseph Joseph Melenhorst, PhD8
AFFILIATIONS
1 Cleveland Clinic, Cleveland, Ohio, United States
2 National Institutes of Health, Bethesda, Maryland, United States
3 Cleveland Clinic, Cleveland, Ohio, United States
4 Cleveland Clinic, Cleveland, Ohio, United States
5 Cleveland Clinic, Cleveland, Ohio, United States
6 Center for Cancer and Immunology Research Children’s National Hospital, Washingtnon, dC, District of Columbia, United States
7 National Institutes of Health, Bethesda, Maryland, United States
8 Cleveland Clinic, Cleveland, Ohio, United States
ABSTRACT
Background: Clinical outcomes after CAR T-cell therapy depend not only on tumor burden and manufacturing variables, but also on the quality of the T-cell compartment available at collection. Patients referred for cellular therapy often carry extensive prior treatment exposure. However, the extent to which prior therapy reshapes the phenotypic and functional starting repertoire remains poorly defined. Whether that remodeling also alters the cytokine output of the collected T cells, with direct implications for cytokine release syndrome (CRS) and immune effector cell-associated HLH-like syndrome (IEC-HS), has not been addressed.
Methods: We performed high-dimensional spectral flow cytometry on 35 apheresis samples from patients with B-cell acute lymphoblastic leukemia (B-ALL) across 2 centers. We stratified patients at a pre-specified threshold of 0-2 versus >2 prior lines of therapy, with therapies including chemotherapy regimens, immunotherapy, or prior CAR, which partitioned the cohort into groups of comparable size. We applied 2 panels in parallel: an Optimized T-cell Immunophenotyping Panel (OTIP; 35 markers) capturing differentiation, activation, proliferation, and checkpoint expression; and a Chemokine Cytokine Receptor panel (CCR) capturing homing receptors, cytolytic machinery, and cytokine output. We ran the CCR panel under resting (R) and 6-hour PMA/ionomycin-stimulated (S) conditions and analyzed approximately 37 million cells. After excluding dead cells, doublets, CD19+ B cells, and CD14+ monocytes, we clustered CD4+ and CD8+ T cells using FlowPy, a Scanpy-based pipeline benchmarked against FlowSOM and manual gating on 30 healthy donors. This resolved 61 clusters across 3 datasets (OTIP, CCR-R, CCR-S). We compared clusters exceeding 1% of the parent gate, containing at least 100 cells, and represented in at least 5 samples per group.
Results: Twenty of 61 clusters differed significantly between therapy-burden groups. Naive-like and early-potential populations were reduced in heavily pretreated patients across both the CD4 and CD8 compartments, and the shift was most pronounced in CD8 cells. OTIP cluster O8P12 (CCR7+CD45RA+TCF1+T-bet-EOMES-) fell from 40.7% to 10.9% (p=0.0001), as did the functionally naive stimulated cluster S8P1, which produced no IFN-γ, TNF-α, or IL-2. Conversely, O8P3 rose from 12.0% to 37.0% (p=0.0010). This population lacked CCR7, TCF1, CD27, and CD28 and expressed CD45RA, CD244, CD226, KLRG1, T-bet, and EOMES, defining a terminal effector state. However, O8P3 retained cytokine competence and lacked a CD39+ terminal exhaustion phenotype, distinguishing it from terminally exhausted cells. Functional profiling identified a parallel expansion of cytokine-producing effectors. IFN-γ+ populations were increased in heavily pretreated patients, most notably in the CD4 compartment (6.1% versus 14.8%, p=0.0008), and the enriched CD8 cluster S8P10 co-expressed IFN-γ, TNF-α, perforin, and granzyme A. Anchoring the OTIP and CCR panels through shared backbone markers reproduced these changes across independent panels. CD4+ and CD8+ naive and CD4+ central memory T cells were reduced, and terminal effector T cells were increased. Notably, type 2 cytokine-producing T cells were preserved across therapy-burden groups.
Conclusions: Increasing prior therapy burden erodes the naive-like T-cell repertoire and enriches differentiated, cytokine-competent effector pools at apheresis. IFN-γ is a central mediator of CRS and IEC-HS. The concurrent expansion of IFN-γ+ CD4 populations therefore suggests that heavily pretreated patients enter manufacturing with a starting repertoire already biased toward high inflammatory output. Preservation of the type 2 compartment indicates that a favorable starting population remains recoverable after extensive treatment. We will test this by integrating disease burden at collection and functionally testing sorted candidate populations transduced with 4-1BBζ versus CD28ζ CD19-targeting? CARs.
DISCLOSURES
Xiaojian Han, MD: No relevant conflicts of interest to declare.